Ting, W.-H.; Chen, H.-H.; Wei, M.-C.; Sun, H.-D.; Hsiao, S.-M.
Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer. Cancers 2024, 16, 3382.
https://doi.org/10.3390/cancers16193382
AMA Style
Ting W-H, Chen H-H, Wei M-C, Sun H-D, Hsiao S-M.
Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer. Cancers. 2024; 16(19):3382.
https://doi.org/10.3390/cancers16193382
Chicago/Turabian Style
Ting, Wan-Hua, Hui-Hua Chen, Ming-Chow Wei, Hsu-Dong Sun, and Sheng-Mou Hsiao.
2024. "Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer" Cancers 16, no. 19: 3382.
https://doi.org/10.3390/cancers16193382
APA Style
Ting, W.-H., Chen, H.-H., Wei, M.-C., Sun, H.-D., & Hsiao, S.-M.
(2024). Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer. Cancers, 16(19), 3382.
https://doi.org/10.3390/cancers16193382